Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Sharpe and Dohme reports positive tafluprost trial data

Merck Sharpe and Dohme reports positive tafluprost trial data

5th May 2011

Merck Sharpe and Dohme has published positive new clinical trial data for tafluprost, its investigational prostaglandin analogue ophthalmic medication.

Data from a phase III study showed that patients with open-angle glaucoma or ocular hypertension were able to experience a reduction in intraocular pressure using the drug that was comparable to the effects of a timolol maleate therapy regimen.

It meant that the compound met its primary efficacy endpoint in the trial, which involved 643 patients and was conducted over a period of 12 weeks.

Data from this trial will support Merck Sharpe and Dohme's efforts to secure regulatory approval for the treatment, which has been licensed as part of an agreement with Santen Pharmaceutical.

Tony Ho, section head of neurology and ophthalmology at Merck, said: "These results provide important insight into the efficacy and tolerability profile of this investigational medicine."

According to its recently published first-quarter financial report, Merck Sharpe and Dohme has experienced growth in the year to date, thanks to demand for drugs such as Januvia and Singulair.ADNFCR-8000103-ID-800520118-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.